Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Block & Leviton LLP Files Securities Class Action Lawsuit Against Abiomed, Inc.

BOSTON, Nov. 16, 2012 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has filed a securities class action on behalf of investors who purchased Abiomed, Inc. ("Abiomed" or the "Company") (NASDAQ: ABMD) stock between August 5, 2011 and October 31, 2012, inclusive (the "Class Period").  The lawsuit, captioned Simon v. Abiomed, Inc., et al., No. 1:12-cv-12137, is pending in the United States District Court for the District of Massachusetts. The lawsuit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

Throughout the Class Period, Defendants touted the Company's financial strength and future prospects.  These statements, however, were materially false and misleading when made because the United States Food and Drug Administration ("FDA") repeatedly warned the Company that its promotional materials contained inappropriate claims regarding the Impella 2.5 catheter and suggested improper off-label uses. Defendants repeatedly assured investors that they had addressed the FDA's concerns and that the matter was resolved.

On November 1, 2012, Abiomed disclosed that the Department of Justice had initiated an investigation "focused on the Company's marketing and labeling of the Impella 2.5."  On this news, shares of Abiomed's stock fell from $19.82 per share on October 31, 2012 to close at $13.61 on November 1, 2012. 

If you are a member of the Class, you may, no later than January 15, 2012, request that the Court appoint you as Lead Plaintiff for the Class.  You may contact the attorneys at Block & Leviton to discuss your rights in the case.  You may also retain counsel of your choice and you need not take any action at this time to be a class member.

Block & Leviton is a Boston-based law firm representing investors for violations of securities laws.  The firm's lawyers have collectively been prosecuting securities cases on behalf of investors for over 50 years. If you have any questions regarding your rights related to this action or have information relevant to the claims asserted in the complaint, please contact attorney Leigh O'Neil of Block & Leviton, LLP at (617) 398-5600 or leigh@blockesq.com.

Contact: BLOCK & LEVITON LLP
Leigh O'Neil
Leigh@blockesq.com                                                      
(617) 398-5600

SOURCE Block & Leviton LLP

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
In today's application economy, enterprise organizations realize that it's their applications that are the heart and soul of their business. If their application users have a bad experience, their revenue and reputation are at stake. In his session at 15th Cloud Expo, Anand Ake...
Having just joined a large technology company with 20 years of history, it would be suicidal to believe that I can immediately move the entire organization to the DevOps mindset and model. For those not familiar with the term, “Eventual Consistency” is a model used in distributed...
If cloud computing benefits are so clear, why have so few enterprises migrated their mission-critical apps? The answer is often inertia and FUD. No one ever got fired for not moving to the cloud – not yet. In his session at 15th Cloud Expo, Michael Hoch, SVP, Cloud Advisory Servi...
Is your organization struggling to deal with skyrocketing volumes of digital assets? The amount of data is growing exponentially and organizations are having a hard time managing this growth. In his session at 15th Cloud Expo, Amar Kapadia, Senior Director of Open Cloud Strategy ...
Video management and delivery has become increasingly challenging due to the diversity of solutions, mobile devices, platforms and video formats. As a result, companies are often required to piece together multiple solutions and vendors to get what they need. In his session at 1...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News

Software Defined Networking (SDN) and Network Function Virtualization (NFV) are tak...